CL2007002598A1 - Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico o una sal del mismo, ciclodextrina y al menos un agente potenciador de la solubilidad; y uso para el tratamiento de un cancer de tumor solido. - Google Patents

Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico o una sal del mismo, ciclodextrina y al menos un agente potenciador de la solubilidad; y uso para el tratamiento de un cancer de tumor solido.

Info

Publication number
CL2007002598A1
CL2007002598A1 CL200702598A CL2007002598A CL2007002598A1 CL 2007002598 A1 CL2007002598 A1 CL 2007002598A1 CL 200702598 A CL200702598 A CL 200702598A CL 2007002598 A CL2007002598 A CL 2007002598A CL 2007002598 A1 CL2007002598 A1 CL 2007002598A1
Authority
CL
Chile
Prior art keywords
quinoliloxi
aquous
cyclodextrine
propanoic
phenoxy
Prior art date
Application number
CL200702598A
Other languages
English (en)
Inventor
Olivier Liu Jiping Ro Dorchies
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2007002598A1 publication Critical patent/CL2007002598A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL200702598A 2006-09-07 2007-09-06 Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico o una sal del mismo, ciclodextrina y al menos un agente potenciador de la solubilidad; y uso para el tratamiento de un cancer de tumor solido. CL2007002598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291410A EP1897542A1 (en) 2006-09-07 2006-09-07 Aqueous formulation comprising an antitumor agent

Publications (1)

Publication Number Publication Date
CL2007002598A1 true CL2007002598A1 (es) 2008-04-18

Family

ID=37728353

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702598A CL2007002598A1 (es) 2006-09-07 2007-09-06 Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico o una sal del mismo, ciclodextrina y al menos un agente potenciador de la solubilidad; y uso para el tratamiento de un cancer de tumor solido.

Country Status (16)

Country Link
EP (2) EP1897542A1 (es)
JP (1) JP2010502691A (es)
KR (1) KR20090050070A (es)
CN (1) CN101511362A (es)
AR (1) AR062674A1 (es)
AU (1) AU2007293174A1 (es)
BR (1) BRPI0717034A2 (es)
CA (1) CA2660685A1 (es)
CL (1) CL2007002598A1 (es)
IL (1) IL197072A0 (es)
MX (1) MX2009002280A (es)
PE (1) PE20081366A1 (es)
RU (1) RU2009112624A (es)
TW (1) TW200817005A (es)
UY (1) UY30579A1 (es)
WO (1) WO2008029282A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2456173A1 (en) * 2001-07-31 2003-02-13 Wayne State University Quinoline derivatives and use thereof as antitumor agents
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents

Also Published As

Publication number Publication date
EP2068876A2 (en) 2009-06-17
KR20090050070A (ko) 2009-05-19
CA2660685A1 (en) 2008-03-13
AR062674A1 (es) 2008-11-26
UY30579A1 (es) 2008-03-31
WO2008029282A2 (en) 2008-03-13
PE20081366A1 (es) 2008-11-28
RU2009112624A (ru) 2010-10-20
BRPI0717034A2 (pt) 2014-05-20
CN101511362A (zh) 2009-08-19
EP1897542A1 (en) 2008-03-12
WO2008029282A3 (en) 2008-05-22
IL197072A0 (en) 2009-11-18
TW200817005A (en) 2008-04-16
AU2007293174A1 (en) 2008-03-13
JP2010502691A (ja) 2010-01-28
MX2009002280A (es) 2009-03-13

Similar Documents

Publication Publication Date Title
BRPI0720169A2 (pt) Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
BRPI0814957A2 (pt) Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
BRPI0920443A2 (pt) compostos de piperazina, agente, e, processo para combater vegetacao indesejavel.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
BRPI0816095A2 (pt) Composto ou um sal do mesmo, pró-droga, agente farmacêutico, métodos para antagonizar um receptor de androgênio e para prevenir / tratar cãncer, e, uso do composto ou uma pró-droga do mesmo.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
CL2007002836A1 (es) Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer.
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
CL2013001202A1 (es) Metodo para prevenir enfermedades de plantas que comprende aplicar un agente para el tratamiento del suelo, donde el agente comprende compuestos derivados de quinolina o sus sales como ingrediente activo.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
CL2008000254A1 (es) Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
SV2011003852A (es) Particulas inhalables que comprenden tiotropio
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2013000513A1 (es) Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.